Emerging biotechnologies: full report - Nuffield Council on Bioethics

E m e r g i n g b i o t e c h n o l o g i e s
role in regulation 8.20
scientists, motives 9.6–9.7, 9.9–9.12
see also charities; industry
procedural narratives 2.36–2.38
procedural virtues 4.43–4.55, 4.57
productivity paradox 1.25, 2.33, 7.20
products 1.13
ambiguous 3.19–3.20
as marketable goods 4.7
profit motive 9.2, 9.5–9.12
promise-requirement cycle 6.45
protocells 2.20, 3.19
public, the 5.7, 5.66
communication of scientists with 5.34–
5.35, 6.51–6.53, 10.10
engaged 5.9–5.19
expectations of research 6.47
the media and 5.10–5.13
sources of information 5.11
publication rates, UK research 7.24, 7.27–7.28
public benefits 4.4
public discourse
in policy making, reduced 7.9
recommendation for conducting 6.53,
10.10
public discourse ethics 4.41–4.55, 10.6–10.7
procedural virtues 4.43–4.55
tool for operationalising 5.2
public engagement 5.2–5.5, 5.20–5.68, 10.7–
10.8
biotechnological exceptionalism 5.61–5.65
bottom-up 5.55–5.57
deliberation and decisiveness 5.43–5.46
dilemmas 5.38–5.60, 5.68
informing and eliciting 5.52–5.54
instrumental rationale 5.26
modes and methods 5.32–5.37
normative rationale 5.25
policy relevance 5.47–5.49
purposes and values 5.28–5.31
rationales for 5.20–5.27
regulatory system 8.29, 8.36, 8.47
<strong>report</strong>ing of outcomes 5.46, 5.68, 10.8
representativeness 5.50–5.51
research policy decisions 7.54–7.55, 10.16
substantive rationale 5.27
top-down 5.55–5.57
upstream 5.40–5.42
vs market forces 5.58–5.60
public ethics 4.2, 4.17–4.59, 5.66, 10.4
applying 4.41–4.55
framing science policy 6.37, 10.9
good faith 4.33
in situ 4.34–4.40
moral mission 4.23–4.27
public good and 4.17–4.19
values underlying 4.28–4.32, 4.56
work of 4.20–4.22
public good(s) 4.6–4.9
commercialisation and 9.71, 10.21
defined 4.6
global 4.8
patent protection 9.13–9.33
public ethics and 4.17–4.19
scientific knowledge as 4.6, 7.33–7.35,
9.13
public harms 4.5
public interest 4.56, 10.4
identifying 4.38–4.39
sources of 4.3–4.16
publicly funded research 6.7–6.10
economic growth agenda 7.10–7.11
influences on researchers 6.23–6.26
justifications for 7.21, 7.33–7.35
need for public engagement 5.61
patent protection and 9.13
policy control of research councils 7.50–
7.56
promoting public good 10.13
public interest in 4.9
role in economic growth 7.36–7.41
public perspectives 5
eliciting 5.54
terminology 5.6–5.8
public private partnerships (PPP) Box 9.3
public reasoning, virtue of 4.49, 6.53
public resources, fair and effective use 4.9
publics 5.7
public sphere 5.7
public values 4.28–4.32, 4.56
quality-adjusted life years (QALYs) 9.57–9.58
quantum dots 2.25
quotas 5.37
random sampling 5.37
rational choice theory 3.21
rational drug design 2.12, 3.24
Rawls, John 4.17
recombinant DNA technology 2.7–2.13, 8.20
reductive approaches, bioscience 6.19
regenerative medicine 2.5–2.6, 7.16
regulation 8, 10.19
accountability 8.24–8.25, 8.29
breaching/breaking the rules 8.28
breadth and depth 8.30
cautionary approaches 8.33–8.38, 8.46
command and control 8.40
coordination 8.27
design 8.41–8.44
flexible 8.41
hard 8.31
light touch 8.41–8.42
multilevel 8.19
national 8.17–8.18
organisation 8.15–8.25
problems 8.26–8.31
public engagement 8.29
I N D E X
205